ClinicalTrials.gg
CompletedNCT01585298STARTUpdated Sep 23, 2019Results posted

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

A Phase 4 interventional study of FTY720 in Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 258 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
6,998
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.

Enrollment
Largest of 34
6,998 · median 167
Started
2012
with 3 others
Phase 4
17 of 34
none open now
Registered
21st of 34
by date
Lead sponsor
20 of 34
Novartis Pharmaceuticals

Among the 34 studies testing fingolimod in Multiple Sclerosis, this one has the largest enrollment, is one of 4 that started in 2012, is one of 17 in phase 4, and was the 21st registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing fingolimod in Multiple Sclerosis, or all of them as a file.
02

Study summary

This study evaluated bradycardiac events during first dose observation of fingolimod in MS patients.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Multiple Sclerosis
  • MS
  • Fingolimod
  • Gilenya
  • ECG
  • Bradyarrythmia
  • conduction abnormalities
  • first dose observation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Subjects with relapsing remitting MS.
  • Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy.
  • Patients who had been previously on therapies. It was understood that these patients satisfied the above mentioned criteria listed under a. in the past.

This also included patients, who were previously treated with fingolimod (regardless of whether or not they had already been treated within the START study) but discontinued treatment due to medical reasons.

- or patients with rapidly evolving severe RRMS (e.g. > 2 relapses with disease progression in one year and > 1 Gd-enhancing lesion or with a significant increase in T2 lesions compared to a recent MRI).

Key Exclusion Criteria:

  • patients
  • active infections
  • pregnant or nursing women, women of unless using 2 reliable forms of
  • presence of (other than localized basal cell carcinoma of the skin).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6,998 participants (actual)

Study arms

  • Experimental
    Fingolimod

    Fingolimod 0.5 mg by mouth once daily for 7 days.

    Drug: FTY720

Interventions

  • DrugFTY720

    Also known as: 0.5 mg gelatin capsules

06

What researchers measure

Primary outcomes

  1. Participants With 2nd or 3rd Degree Atrioventricular (AV) Block

    AV Blocks/Heart block is an abnormal heart rhythm where the heart beats too slowly; the electrical signals that tell the heart to contract are partially intermittent (Type 2:1) or slowed (1st and 2nd degree) or blocked (3rd degree) between the upper chambers (atria) and the lower chambers (ventricles). In 2nd degree AV Blocks, electrical impulses are intermittent (type 2:1) or delayed w/ each subsequent heartbeat (Mobitz type I) until a beat fails to reach the ventricles entirely. This type of block often is physiologic and observed in a highly relaxed state \& during sleep. In 2nd degree AV Blocks type II, the atria electrical impulses are unable to reach the ventricles, a more serious condition. In 3rd degree AV Blocks (complete heart block), none of the electrical impulses reach either the atria or the ventricles. Patients can experience simultaneously both types of 2nd or 3rd degree AV Blocks without any symptoms.

    Time frame: baseline, during 6 hour monitoring post first dose observation

  2. Number of Patients With Heart Rate Below 45 Beats Per Minute (BPM)

    Number of patients with heart rate below 45 beats bpm in ECG during first dose observation

    Time frame: baseline during 6 hour monitoring post dose

Secondary outcomes

  1. Number of Participants With Prolonged QTc Interval (Friderica)

    Number of patients with conduction abnormalities such as QT prolongation, first degree AV block during treatment initiation. The QT interval is a period between the activation and the regeneration of ventricular contraction. A prolonged QT interval can be a potential marker of cardiac arrhythmias. Two patients of the safety analysis set discontinued the study without having received treatment, but safety information was collected on these two patients.

    Time frame: baseline post-dose

  2. Number of Participants With Bradyarrhythmic Electrocardiogram (ECG) Events

    The number of participants with bradyarrhythmic electrocardiogram (ECG) events was assessed. Bradyarrhythmic ECG events are defined as QTc Fridericia time \> 450 ms for males and \> 470 ms for females.

    Time frame: up to day 7

  3. Number of Patients With Cardiac Adverse Events

    The number of participants with the occurrence of subsequent cardiac adverse events (AEs) and serious cardiac AEs during study was assessed. Cardiac events were defined as the following Medical Dictionary for Regulatory Activities (MedDRA) preferred terms: angina pectoris, chest discomfort, dizziness, dyspnoea, dyspnoea exertional, fatigue, palpitations, syncope, vertigo, vertigo positional and vision blurred.

    Time frame: 7 days

07

Results

Posted Sep 23, 2019
Limitations and caveats
292 centers were initiated but 278 centers randomized patients.

Participant flow

Participant flow — Overall Study
MilestoneFingolimod
Started6998
Completed6961
Not completed37
Withdrew: Study completion was not documented.1
Withdrew: Protocol deviation1
Withdrew: Administrative problems4
Withdrew: Lost to follow-up2
Withdrew: Withdrawal by subject4
Withdrew: Abnormal test procedure results1
Withdrew: Adverse event24

Outcome measures

PrimaryParticipants With 2nd or 3rd Degree Atrioventricular (AV) Block

AV Blocks/Heart block is an abnormal heart rhythm where the heart beats too slowly; the electrical signals that tell the heart to contract are partially intermittent (Type 2:1) or slowed (1st and 2nd degree) or blocked (3rd degree) between the upper chambers (atria) and the lower chambers (ventricles). In 2nd degree AV Blocks, electrical impulses are intermittent (type 2:1) or delayed w/ each subsequent heartbeat (Mobitz type I) until a beat fails to reach the ventricles entirely. This type of block often is physiologic and observed in a highly relaxed state \& during sleep. In 2nd degree AV Blocks type II, the atria electrical impulses are unable to reach the ventricles, a more serious condition. In 3rd degree AV Blocks (complete heart block), none of the electrical impulses reach either the atria or the ventricles. Patients can experience simultaneously both types of 2nd or 3rd degree AV Blocks without any symptoms.

Time frame:
baseline, during 6 hour monitoring post first dose observation
Reported as:
Number · Participants
Participants With 2nd or 3rd Degree Atrioventricular (AV) Block
ParticipantsFingolimod
Any AV block ll degree or higher120
AV block ll degree: Mobitz type I degree117
AV block II degree: Mobitz type II degree0
AV block II degree: 2:143
AV block III degree1
PrimaryNumber of Patients With Heart Rate Below 45 Beats Per Minute (BPM)

Number of patients with heart rate below 45 beats bpm in ECG during first dose observation

Time frame:
baseline during 6 hour monitoring post dose
Reported as:
Number · Participants
Number of Patients With Heart Rate Below 45 Beats Per Minute (BPM)
ParticipantsFingolimod
Number of Patients With Heart Rate Below 45 Beats Per Minute (BPM)63
SecondaryNumber of Participants With Prolonged QTc Interval (Friderica)

Number of patients with conduction abnormalities such as QT prolongation, first degree AV block during treatment initiation. The QT interval is a period between the activation and the regeneration of ventricular contraction. A prolonged QT interval can be a potential marker of cardiac arrhythmias. Two patients of the safety analysis set discontinued the study without having received treatment, but safety information was collected on these two patients.

Time frame:
baseline post-dose
Reported as:
Number · Participants
Number of Participants With Prolonged QTc Interval (Friderica)
ParticipantsFingolimod
Female, QTcFridericia Interval > 470 ms7
Male, QTcF Interval > 450 ms6
SecondaryNumber of Participants With Bradyarrhythmic Electrocardiogram (ECG) Events

The number of participants with bradyarrhythmic electrocardiogram (ECG) events was assessed. Bradyarrhythmic ECG events are defined as QTc Fridericia time \> 450 ms for males and \> 470 ms for females.

Time frame:
up to day 7
Reported as:
Number · Participants
Number of Participants With Bradyarrhythmic Electrocardiogram (ECG) Events
ParticipantsFingolimod
Number of Participants With Bradyarrhythmic Electrocardiogram (ECG) Events26
SecondaryNumber of Patients With Cardiac Adverse Events

The number of participants with the occurrence of subsequent cardiac adverse events (AEs) and serious cardiac AEs during study was assessed. Cardiac events were defined as the following Medical Dictionary for Regulatory Activities (MedDRA) preferred terms: angina pectoris, chest discomfort, dizziness, dyspnoea, dyspnoea exertional, fatigue, palpitations, syncope, vertigo, vertigo positional and vision blurred.

Time frame:
7 days
Reported as:
Number · Participants
Number of Patients With Cardiac Adverse Events
ParticipantsFingolimod
Cardiac events489
Serious cardiac AEs9

Adverse events

Collected over Adverse events (AEs) were collected for each patient from first administration of study drug until end of study visit, usually for one week. Furthermore, serious suspected adverse drug reactions (SADRs) had to be documented until 6 weeks after the patient has stopped study participation.. Non-serious events are listed at a 0.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fingolimod—160/6,998 (2.3%)2,179/6,998 (31.1%)
Most frequent serious events
Showing 10 of 75
Most frequent serious events
EventFingolimod
Atrioventricular block second degreeCardiac disorders49/6998
Multiple sclerosis relapseNervous system disorders26/6998
BradycardiaCardiac disorders24/6998
Electrocardiogram QT prolongedInvestigations4/6998
Heart rate decreasedInvestigations4/6998
Atrial fibrillationCardiac disorders3/6998
DizzinessNervous system disorders3/6998
Optic neuritisNervous system disorders3/6998
HypertensionVascular disorders3/6998
Coronary artery diseaseCardiac disorders2/6998
Most frequent other events
Showing 10 of 439
Most frequent other events
EventFingolimod
HeadacheNervous system disorders316/6998
FatigueGeneral disorders227/6998
NauseaGastrointestinal disorders143/6998
NasopharyngitisInfections and infestations137/6998
DizzinessNervous system disorders126/6998
LymphopeniaBlood and lymphatic system disorders119/6998
Atrioventricular block first degreeCardiac disorders116/6998
DiarrhoeaGastrointestinal disorders96/6998
Atrioventricular block second degreeCardiac disorders74/6998
Multiple sclerosis relapseNervous system disorders70/6998

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Fingolimod
Mean39.2 ± 10.52
Sex: Female, Male
Sex: Female, Male(Participants)Fingolimod
Female4924
Male2074
08

Study locations

258 sites
  • Novartis Investigative Site
    Ostfildern, Baden-Wurttemberg 73760, Germany
  • Novartis Investigative Site
    Munich, Bavaria 81241, Germany
  • Novartis Investigative Site
    Altenholz-Stift, Germany 24161, Germany
  • Novartis Investigative Site
    Cologne, North Rhine-Westphalia 50937, Germany
  • Novartis Investigative Site
    Flensburg, Schleswig-Holstein 24939, Germany
  • Novartis Investigative Site
    Aachen, 52062, Germany
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Aalen, 73430, Germany
  • Novartis Investigative Site
    Aalen-Wasseralfingen, 73433, Germany
  • Novartis Investigative Site
    Abensberg, 93326, Germany
  • Novartis Investigative Site
    Achim, 28832, Germany
  • Novartis Investigative Site
    Aichach, 86551, Germany
  • Novartis Investigative Site
    Altenburg, 04600, Germany
  • Novartis Investigative Site
    Alzenau in Unterfranken, 63755, Germany
  • Novartis Investigative Site
    Andernach, 56626, Germany
  • Novartis Investigative Site
    Asbach, 53567, Germany
  • Novartis Investigative Site
    Aschaffenburg, 63739, Germany
  • Novartis Investigative Site
    Augsburg, 86179, Germany
  • Novartis Investigative Site
    Bad Berka, 99437, Germany
  • Novartis Investigative Site
    Bad Hersfeld, 36251, Germany
  • Novartis Investigative Site
    Bad Homburg, 61348, Germany
  • Novartis Investigative Site
    Bad Honnef, 53604, Germany
  • Novartis Investigative Site
    Bad Krozingen, 79189, Germany
  • Novartis Investigative Site
    Bad Mergentheim, 97980, Germany
  • Novartis Investigative Site
    Bad Saarow, 15526, Germany
  • Novartis Investigative Site
    Bad Wildbad, 75323, Germany
  • Novartis Investigative Site
    Bamberg, 96052, Germany
  • Novartis Investigative Site
    Bayreuth, 95445, Germany
  • Novartis Investigative Site
    Berg, 82335, Germany
  • Novartis Investigative Site
    Bergisch Gladbach, 51429, Germany
  • Novartis Investigative Site
    Berlin, 10178, Germany
  • Novartis Investigative Site
    Berlin, 10365, Germany
  • Novartis Investigative Site
    Berlin, 10437, Germany
  • Novartis Investigative Site
    Berlin, 10713, Germany
  • Novartis Investigative Site
    Berlin, 120999, Germany
  • Novartis Investigative Site
    Berlin, 12101, Germany
  • Novartis Investigative Site
    Berlin, 12163, Germany
  • Novartis Investigative Site
    Berlin, 12351, Germany
  • Novartis Investigative Site
    Berlin, 12587, Germany
  • Novartis Investigative Site
    Berlin, 12621, Germany
  • Novartis Investigative Site
    Berlin, 13347, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Berlin, 13465, Germany
  • Novartis Investigative Site
    Berlin, 13507, Germany
  • Novartis Investigative Site
    Berlin, 14059, Germany
  • Novartis Investigative Site
    Berlin, 14163, Germany
  • Novartis Investigative Site
    Berlin, 14169, Germany
  • Novartis Investigative Site
    Bielefeld, 33602, Germany
  • Novartis Investigative Site
    Bielefeld, 33647, Germany
  • Novartis Investigative Site
    Bochum, 44787, Germany
  • Novartis Investigative Site
    Bochum, 44789, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Bochum, 44795, Germany
  • Novartis Investigative Site
    Bochum, 44869, Germany
  • Novartis Investigative Site
    Bogen, 94327, Germany
  • Novartis Investigative Site
    Bonn, 53111, Germany
  • Novartis Investigative Site
    Borna, 04552, Germany
  • Novartis Investigative Site
    Bottrop, 46236, Germany
  • Novartis Investigative Site
    Böblingen, 71032, Germany
  • Novartis Investigative Site
    Braunschweig, 38100, Germany
  • Novartis Investigative Site
    Braunschweig, 38114, Germany
  • Novartis Investigative Site
    Bremen, 28755, Germany
  • Novartis Investigative Site
    Bruchsal, 76646, Germany
  • Novartis Investigative Site
    Buchholz, 21244, Germany
  • Novartis Investigative Site
    Buchholz in der Nordheide, 21244, Germany
  • Novartis Investigative Site
    Butzbach, 35510, Germany
  • Novartis Investigative Site
    Celle, 29223, Germany
  • Novartis Investigative Site
    Chemnitz, 09117, Germany
  • Novartis Investigative Site
    Cologne, 50674, Germany
  • Novartis Investigative Site
    Cologne, 50935, Germany
  • Novartis Investigative Site
    Cologne, 51109, Germany
  • Novartis Investigative Site
    Delbrück, 33129, Germany
  • Novartis Investigative Site
    Dessau, 06846, Germany
  • Novartis Investigative Site
    Dillingen, 66763, Germany
  • Novartis Investigative Site
    Dillingen, 89407, Germany
  • Novartis Investigative Site
    Dortmund, 44135, Germany
  • Novartis Investigative Site
    Dortmund, 44137, Germany
  • Novartis Investigative Site
    Dresden, 01067, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Düren, 52351, Germany
  • Novartis Investigative Site
    Düsseldorf, 40211, Germany
  • Novartis Investigative Site
    Düsseldorf, 40225, Germany
  • Novartis Investigative Site
    Düsseldorf, 40479, Germany
  • Novartis Investigative Site
    Düsseldorf, 40625, Germany
  • Novartis Investigative Site
    Eberswalde, 16225, Germany
  • Novartis Investigative Site
    Eisenach, 99817, Germany
  • Novartis Investigative Site
    Eisleben Lutherstadt, 06295, Germany
  • Novartis Investigative Site
    Eltville, 65343, Germany
  • Novartis Investigative Site
    Emden, 26721, Germany
  • Novartis Investigative Site
    Emmendingen, 79312, Germany
  • Novartis Investigative Site
    Erbach im Odenwald, 64711, Germany
  • Novartis Investigative Site
    Erfurt, 99089, Germany
  • Novartis Investigative Site
    Erfurt, 99096, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Eschwege, 37269, Germany
  • Novartis Investigative Site
    Essen, 45131, Germany
  • Novartis Investigative Site
    Essen, 45138, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Essen, 45257, Germany
  • Novartis Investigative Site
    Frankfurt, 60313, Germany

Showing the first 100 of 258 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Limmroth V, Ziemssen T, Lang M, Richter S, Wagner B, Haas J, Schmidt S, Gerbershagen K, Lassek C, Klotz L, Hoffmann O, Albert C, Schuh K, Baier-Ebert M, Wendt G, Schieb H, Hoyer S, Dechend R, Haverkamp W. Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study. BMC Neurol. 2017 Jan 18;17(1):11. doi: 10.1186/s12883-016-0789-7. PubMed 28100182 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2012 to primary completion in Dec 2016, 55 months.

Results were first posted in Sep 2019, 2 years 9 months after primary completion.

Of 36 industry-sponsored phase 4 interventional studies under Multiple Sclerosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 55 months is above that.

Counting every sponsor, half of 69 studies reached it within 34 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2012
First posted
Apr 25, 2012
StartActual
Apr 29, 2012
Primary completionActual
Dec 12, 2016
CompletionActual
Dec 12, 2016
Results first posted
Sep 23, 2019
Last update
Sep 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01585298
Responsible party
Sponsor
First posted
Apr 25, 2012
Start date
Apr 29, 2012
Primary completion
Dec 12, 2016
Completion
Dec 12, 2016
Results posted
Sep 23, 2019
Last update
Sep 23, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion